Kymera Therapeutics

Today we shared our third quarter 2026 financial results and reported positive data from the Phase 1 healthy volunteer trial of KT-579, our investigational, first-in-class, oral IRF5 degrader. Join our video webcast today to learn more about this novel program and how we’re advancing an industry-leading pipeline of oral medicines in immunology with the potential to transform patients’ lives: bit.ly/4koh5U1 #RevolutionizingImmunology

$KYMR Join us on October 29 for our quarterly financial results and latest company updates: bit.ly/47CrpQP

We’re excited to share that Kymera has been named a finalist for the 2026 @Citeline Scrip Awards! Our BroADen Phase 1b atopic dermatitis trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, was shortlisted in the Clinical Advance of the Year – Early Stage Editor’s Choice category. We’re proud to see the incredible work of the Kymera team recognized alongside this year’s finalists.

Our CEO, @NelloMainolfi, joined @rahulc and @Biotech2050Pod to discuss the science and strategy behind targeted protein degradation, building a fully integrated biopharma company, and the potential to unlock new possibilities for millions of patients. Check out the full episode!

$KYMR Explore our upcoming investor events in September in our latest press release: bit.ly/4zU2R2F

We’re looking forward to the #ERSCongress and #EADVCongress this month. Visit the Kymera booth and check out our poster presentations featuring KT-621, our investigational, first-in-class, oral STAT6 degrader. Hope to see you there! Learn more: bit.ly/4gs7o4O #EADV2026 #ERS2026 #RevolutionizingImmunology

In the latest edition of the New Paradigms newsletter, Kymera founders @NelloMainolfi and @LifeSciVC reflect on the founding thesis behind Kymera and the early decisions that helped shape the company we are today. Watch the full conversation to hear how those ideas continue to inform the path ahead!

Today we shared our second quarter 2026 financial results and highlighted recent company updates and upcoming milestones. Discover how we’re advancing an industry leading pipeline of oral small molecule degrader medicines in immunology with the potential to transform patients’ lives around the world: bit.ly/4z3yA12 #RevolutionizingImmunology $KYMR

$KYMR Join us on August 5th for our quarterly financial results and latest company updates: bit.ly/4yMAbbd

Today, we announced the appointment of Terence Rooney, MD, as Chief Medical Officer. Terence brings deep immunology drug development experience to Kymera as we advance our oral immunology portfolio and work to expand treatment options for patients living with immuno-inflammatory diseases. Welcome to the team, Terence! Read more: bit.ly/4x0uSDq

This morning, our CEO, @NelloMainolfi, will join fellow biopharma leaders at the @BiotechTV U.S. Science Summit to discuss the state of innovation and how bold ideas and a shared commitment to impact can advance drug discovery and shape the future of healthcare. Follow along on @BiotechTV's channels for event highlights!

Thrilled to be at the @AADskin Innovation Academy this week, connecting with the dermatology community and discussing novel approaches with the potential to shape the future of patient care. Stop by our poster presentation to learn more about KT-621, our investigational, first-in-class, oral STAT6 degrader. #RevolutionizingImmunology #AADInnovation2026

Our Founder, President & CEO @NelloMainolfi joined @CNBCFastMoney to discuss the momentum behind KT-621, our vision for advancing a new generation of oral medicines, and how we're working to transform treatment for patients living with chronic inflammatory diseases. Watch the full interview: bit.ly/3T6NJhn #RevolutionizingImmunology $KYMR

Today, we announced the appointment of Elizabeth Laws as Senior Vice President, KT-621 Development Program Leader. Liz brings extensive experience across immunology clinical development, global franchise strategy and commercialization to Kymera as we continue advancing KT-621, our investigational, first-in-class, oral STAT6 degrader, as a potential paradigm-shifting oral therapy for multiple Type 2 inflammatory diseases. Welcome to the team, Liz! bit.ly/4p3ifog #RevolutionizingImmunology

Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release: bit.ly/4baOiNk

We’re proud to join the @AllergyAsthmaHQ Corporate Council and support AAN’s important work advancing patient-centered research, education, advocacy, and access to care for people living with asthma, allergies, and related conditions. We look forward to partnering with the AAN team and their community to help improve the lives of patients and their families.

We’re looking forward to an impactful few days in Nashville at the Revolutionizing Atopic Dermatitis conference, where the dermatology community will come together to discuss unmet patient needs and emerging therapeutic approaches in atopic dermatitis. Stop by our exhibition table and poster presentation on KT-621, our investigational, first-in-class, oral STAT6 degrader, to learn more! #RAD2026 #RevolutionizingImmunology

At the Japanese Dermatological Association Annual Meeting, we presented Phase 1 data in healthy Japanese adults for KT-621, our investigational, first-in-class, oral STAT6 degrader. The presentation highlights KT-621’s compelling profile and its potential to transform treatment paradigms for patients living with chronic Type 2 inflammatory conditions. Learn more in our latest press release: bit.ly/443iypp #RevolutionizingImmunology

Today, we announced that the first participant has been dosed in the Phase 1 clinical trial of KT-485, our oral, potent and selective IRAK4 degrader being advanced by @sanofi under our collaboration. This milestone marks an important step forward for KT-485 and its potential to offer a novel oral approach to addressing a key pathway involved in several immuno-inflammatory conditions. Read the full press release: bit.ly/4dYogPj #RevolutionizingImmunology